Holen Sie sich die Stockscreener-App
5.03
1.82%
0.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS - ChartMill
Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline - Investing.com
Earnings call transcript: Myriad Genetics Q1 2026 results show mixed performance - Investing.com Canada
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2% - Yahoo Finance
Myriad Genetics (NASDAQ: MYGN) Q1 2026 revenue up 2% as loss widens - Stock Titan
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business - ChartMill
MSN Money - MSN
Myriad Genetics Q1 2026 earnings preview - MSN
Myriad Genetics (NASDAQ: MYGN) CCO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Myriad Genetics introduces FirstGene Multiple Prenatal Screen at ACOG2026 with interactive experience - Traders Union
RS Investment Management's Myriad Genetics Inc(MYGN) Holding History - GuruFocus
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Only 13% say first depression medication worked, Myriad survey finds - Stock Titan
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan - ChartMill
Myriad Genetics to unveil advanced decision-support tools in cancer care at ASCO26 - Traders Union
Analysts estimate Myriad Genetics (MYGN) to report a decline in earnings: What to look out for - MSN
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 - ChartMill
Myriad Genetics (MYGN) to Release Quarterly Earnings on Tuesday - MarketBeat
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Myriad Genetics Q3 2025 Earnings Preview - MSN
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Myriad Genetics unveils FirstGene Multiple Prenatal Screen at Washington D.C. symposium - Traders Union
Polygenic Risk Score Testing Market Booming with Rapid Growth - openPR.com
Print Article - CMAJ
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics announces CFO appointment - MSN
Small-Cap Stocks: Krispy Kreme, Myriad Genetics, and Hamilton Insurance Group to AvoidNews and Statistics - IndexBox
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? - MSN
Forbes ranks Myriad Genetics among top U.S. employers for company culture in 2026 - Traders Union
MYGN Financials: Income Statement, Balance Sheet & Cash Flow | Myriad Genetics - Stock Titan
EPO Biomarkers Market Outlook 2026-2033: Growth Drivers, - openPR.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Myriad Genetics (MYGN) to Present at AACR Annual Meeting 2026 - GuruFocus
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - GlobeNewswire
Breast cancer treatment data lead Myriad's 2 AACR podium talks - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat
Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan
Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat
[ARS] MYRIAD GENETICS INC SEC Filing - Stock Titan
Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan
Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan
Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
0.34%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):